Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas | Regeneron Pharmaceuticals Inc.
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron, consisting of a $50M upfront payment and $75M equity commitment, with up to approximately
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas May 18, 2026 at 7:00 AM EDT PDF Version The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron , consisting of a $50M upfront payment and $75M equity commitment, with up to approximately $2.2B in additional potential milestone payments plus tiered royalties TARRYTOWN, N.Y. , May 18, 2026 (GLOBE NEWSWI
related reading
- Neion Bioneionbio.com
- The 23andMe Deal - Cremieux Recueilcremieux.xyz
- Multiply Labs | Robotic Biomanufacturing Infrastructuremultiplylabs.com
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseasesanofi.com
- News — Pacific 8 Venturespac8.com
- Medicine's Endgamenotboring.co
- Curie.Biocurie.bio
- Treeline | Blogtreeline.bio
- Helion Energy - Wikipediaen.wikipedia.org
- NewLimit raises $435M led by Founders Fund to bring longevity medicines to human trialsblog.newlimit.com
- GSK and Vir Biotechnology enter collaboration to find coronavirus solutions | GSKgsk.com